Saponin QA-21V1 clinical trials
Also written QS21.
How each study uses saponin QA-21V1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the saponin QA-21V1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 1998 (4)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1998 | 4 |
| 1999 | 2 |
| 2000 | 3 |
| 2001 | 1 |
| 2002 | 1 |
| 2007 | 3 |
| 2009 | 2 |
| 2012 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 20
Memorial Sloan Kettering Cancer Center (10) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Pfizer (4) · Agenus Inc. (2) · University of Kansas Medical Center (1) · U.S. Army Medical Research and Development Command (1) · University of Virginia (1) · Fox Chase Cancer Center (1)
Often tested with
Tested in the same studies.
Vanutide cridificar (4) · HIV Envelope Protein gp120 (2) · GM2-KLH Vaccine (2) · Apricoxib (1) · Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017 (1) · Incomplete Freund's adjuvant (1) · MUC1-KLH Conjugate Vaccine (1) · MUC1-KLH Vaccine/QS21 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test saponin QA-21V1.
- Jul 2027BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ TransplantsPhase 1 · Ohio State University Comprehensive Cancer Center
Studies
Open first, then newest update. How each study uses saponin QA-21V1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ TransplantsRecruitingPhase 1Ohio State University Comprehensive Cancer CenterNCT06741072Written as QS21How we know
- PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19CompletedPhase 1U.S. Army Medical Research and Development CommandNCT04784767Written as 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)How we know
- Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic CancerActive, not recruitingPhase 2University of Kansas Medical CenterNCT05638698Written as QS-21How we know
- Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00579423Written as QS21How we know
- Phase 1a Study to Evaluate Immunogenicity of ASV®CompletedPhase 1Agenus Inc.NCT03673020Written as ASV® AGEN2017 + QS-21 Stimulon® adjuvantHow we know
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001044Written as QS-21How we know
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001096Written as QS-21How we know
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001052Written as QS-21How we know
- Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000809Written as QS-21How we know
- Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital HerpesCompletedPhase 2Agenus Inc.NCT01687595Written as HerpV and QS-21How we know
- Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00955409Written as ACC-001(3µg) + QS21How we know
- Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast CancerCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT00470574Written as QS21How we know
- A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2PfizerNCT00960531Written as ACC-001+ QS21 (3mcg)How we know
- Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00479557Written as ACC-001 + QS-21How we know
- Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00498602Written as ACC-001 + QS-21How we know
- Vaccine Therapy in Treating Patients at High Risk for Breast Cancer RecurrenceCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT00030823Written as QS21How we know
- Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedPhase 1University of VirginiaNCT00003224Written as QS21How we know
- Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal CancerCompletedPhase 1Fox Chase Cancer CenterNCT00006387Written as QS21How we know
- Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced MelanomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00003362Written as QS21How we know
- Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00006041Written as QS21How we know
See all 26 studies that test saponin QA-21V1 →
Given beside what is tested · 6 — saponin QA-21V1 is usual care or a partner of the new treatment
- RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEVRecruitingPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT06484335Written as ALFQHow we know
- Safety and Immunogenicity of CJCV2 With and Without ALFQCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05500417Written as ALFQHow we know
- HIV Vaccine in HIV-uninfected AdultsCompletedPhase 1U.S. Army Medical Research and Development CommandNCT04658667Written as ALFQHow we know
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05769569Written as ALFQHow we know
- A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownPhase 1U.S. Army Medical Research and Development CommandNCT04268420Written as ALFQHow we know
- A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownPhase 1U.S. Army Medical Research and Development CommandNCT04296279Written as ALFQHow we know
Codes
What other systems call saponin QA-21V1 · ClinicalTrials.gg INT003688
- MeSH (NLM) C078785saponin QA-21V1One source NLM
- UNII (FDA) 61H83WZX3UQUILLAJA SAPONIN (QS-21)Confirmed FDA, NLM
- RxNorm 2002417One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C078785 | saponin QA-21V1 | One source NLM |
| UNII (FDA) | 61H83WZX3U | QUILLAJA SAPONIN (QS-21) | Confirmed FDA, NLM |
| RxNorm | 2002417 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.